2023•Value in HealthOpen access

EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK

Beckley Miller, Monika Russel-Szymczyk, I. Jensen, A. Shah, S.T. Alexopoulos, Alex Herbert, Thomas W. McLean, Namita Tundia

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Relapsing remitting, Cladribine, Multiple sclerosis, Medicine, Oncology, Internal medicine, Immunology

Back to paper search Browse research topics Original source

EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK — Research Paper | ScholarLens